Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

98 questions · 107 findings · 10 reviews

No studies found 25 · 23.4%GRADE not reported 11 · 10.3%Very low 23 · 21.5%Low 26 · 24.3%Moderate 14 · 13.1%High 8 · 7.5%

Combination chemotherapy vs single‐agent chemotherapy

Overall survival (3 years) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery

It is very uncertain whether combination chemotherapy changes overall survival (3 years) compared with single‐agent chemotherapy (very low certainty).

1 finding from 1 review

Combination chemotherapy vs single‐agent chemotherapy

Disease-free survival · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery

It is very uncertain whether combination chemotherapy changes disease‐free survival (3 years) compared with single‐agent chemotherapy (very low certainty).

1 finding from 1 review

Combination chemotherapy vs single‐agent chemotherapy

Complete response rate after preoperative chemoradiation (ypCR) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery

Combination chemotherapy leads to higher complete response rate after preoperative chemoradiation (ypCR) compared with single‐agent chemotherapy (high certainty).

1 finding from 1 review

Combination chemotherapy vs single‐agent chemotherapy

Toxicity ‐ early adverse events G3/4 · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery

Combination chemotherapy probably leads to higher toxicity ‐ early adverse events G3/4 compared with single‐agent chemotherapy (moderate certainty).

1 finding from 1 review

Combination chemotherapy vs single‐agent chemotherapy

Metastases intra‐abdominal · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery

Combination chemotherapy showed no clear difference in metastases intra‐abdominal compared with single‐agent chemotherapy (moderate certainty).

1 finding from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + GLP1‐A
2 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + DPP4‐I

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + DPP4‐I compared with metformin plus another antidiabetic drug (very low certainty).

3 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + thiazolidinedione

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + thiazolidinedione compared with metformin plus another antidiabetic drug (very low certainty).

2 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + nateglinide
4 findings from 1 review
Show 1 more finding

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + SGLT2‐I

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + SGLT2‐I compared with metformin plus another antidiabetic drug (very low certainty).

2 findings from 1 review